High-on-Aspirin Residual Platelet Reactivity Evaluated Using the Multiplate^® Point-of-Care Device

1. Eikelboom JW, Hirsh J, Spencer FA, et al. Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e89S-119S.10.1378/chest.11-2293Search in Google Scholar

2. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and secondary prevention of cardiovascular disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence- Based Clinical Practice Guidelines. Chest 2012;141(2 Suppl):e637S-68S.10.1378/chest.141.4.1129cSearch in Google Scholar

3. Baigent C, Blackwell L, Collins R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (London, England). 2009;373(9678):1849-60.10.1016/S0140-6736(09)60503-1Search in Google Scholar

4. Pettersen A a., Arnesen H, Seljeflot I. A brief review on high on-aspirin residual platelet reactivity. Vascul Pharmacol. 2015;67-69:6-9.10.1016/j.vph.2015.03.01825869498Search in Google Scholar

5. Pedersen SB, Grove EL, Nielsen HL, et al. Evaluation of aspirin response by Multiplate whole blood aggregometry and light transmission aggregometry. Platelets. 2009;20(6):415-20.10.1080/0953710090310064319658002Search in Google Scholar

6. Kovács EG, Katona É, Bereczky Z, et al. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. Thromb Res 2014;33(5):811-6.10.1016/j.thromres.2013.10.00824207016Search in Google Scholar

7. Kernan WN, Ovbiagele B, Black HR, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: A guideline for healthcare professionals from the American Heart Association/ American Stroke Association. Stroke. 2014.10.1161/STROKEAHA.115.00866125744519Search in Google Scholar

8. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001;345(25):1809-17.10.1056/NEJMoa00319911752357Search in Google Scholar

9. Fitzgerald DJ, Maree A. Aspirin and clopidogrel resistance. Hematology Am Soc Hematol Educ Program .2007;(1):114-20.10.1182/asheducation-2007.1.11418024618Search in Google Scholar

10. Malinin AI, Ong S, Makarov LM, et al. Platelet inhibition beyond conventional antiplatelet agents: expanding role of angiotensin receptor blockers, statins and selective serotonin reuptake inhibitors. Int J Clin Pract. 2006;60(8):993-1002.10.1111/j.1742-1241.2006.01063.x16893441Search in Google Scholar

11. Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet (London, England). 2006;367(9510):606-17.10.1016/S0140-6736(06)68040-9Search in Google Scholar

12. Feher G, Koltai K, Papp E, et al. Aspirin resistance: possible roles of cardiovascular risk factors, previous disease history, concomitant medications and haemorrheological variables. Drugs Aging. 2006;23(7):559-67.10.2165/00002512-200623070-0000216930084Search in Google Scholar

13. Uzun F, Biyik I, Akturk IF, et al. Antiplatelet resistance and the role of associated variables in stable patients treated with stenting. Postępy w Kardiol interwencyjnej = Adv Interv Cardiol. 2015;11(1):19-25.10.5114/pwki.2015.49180437262725848366Search in Google Scholar

14. Liu X-F, Cao J, Fan L, et al. Prevalence of and risk factors for aspirin resistance in elderly patients with coronary artery disease. J Geriatr Cardiol. 2013;10(1):21-7.Search in Google Scholar

15. Akoglu H, Agbaht K, Piskinpasa S, et al. High frequency of aspirin resistance in patients with nephrotic syndrome. Nephrol Dial Transplant. 2012;27(4):1460-6.10.1093/ndt/gfr47621865214Search in Google Scholar

16. Kameda S, Sakata T, Kokubo Y, et al. Association of platelet aggregation with lipid levels in the Japanese population: the Suita study. J Atheroscler Thromb. 2011;18(7):560-7.10.5551/jat.628821427509Search in Google Scholar